C2N Diagnostics Accelerates Global Expansion with Six New International Partnerships to Broaden Access to Alzheimer’s Blood Testing
C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company committed to its mission of delivering Clarity Through Innovation®, has taken a significant step toward making advanced Alzheimer’s disease diagnostics more accessible around the world. Building on its existing network of collaborations, the company has announced the addition of six new partnerships with clinical reference laboratories and healthcare distributors. These alliances will enable healthcare providers in more than seven additional countries to access C2N’s groundbreaking PrecivityAD2™ blood test, an innovative tool for aiding the diagnosis of Alzheimer’s disease.
The PrecivityAD2™ test is designed to identify the presence or absence of amyloid pathology in the brain — a well-established hallmark of Alzheimer’s disease — through a simple, non-invasive blood draw. This diagnostic advance is particularly valuable for patients undergoing evaluation for cognitive complaints, offering an alternative to more invasive and costly methods such as cerebrospinal fluid (CSF) collection or amyloid PET imaging. By expanding its global footprint, C2N is opening doors for earlier detection, more informed clinical decision-making, and better patient care worldwide.
Six Strategic Partnerships Spanning Multiple Continents
C2N’s newly formed relationships with leading diagnostic and healthcare organizations mark an important milestone in its international growth strategy. These partnerships include:
- Accuserv Diagnostic Center – Serving the Philippines, Accuserv is known for providing high-quality laboratory testing to meet the country’s increasing demand for advanced diagnostic services.
- Archerfish Precision Diagnostics – Based in Singapore and active across other Southeast Asian markets, Archerfish specializes in cutting-edge precision medicine diagnostics. (More information is available through Archerfish’s own corporate news release.)
- Codex Genetics – Headquartered in Hong Kong, Codex Genetics integrates advanced diagnostics with digital health solutions to provide personalized insights for complex diseases.
- Dr. Dangs Lab – A highly respected name in India’s clinical diagnostics landscape, Dr. Dangs Lab offers a broad spectrum of medical testing services, with a strong focus on accuracy and patient care.
- Medical Link – Operating in Israel, Medical Link is a trusted healthcare distributor with expertise in introducing innovative medical technologies to the region.
- Milenia Labs – Serving Costa Rica and Mexico, Milenia Labs is known for expanding access to specialized diagnostics across Latin America.
With these collaborations, C2N’s international reach will now encompass additional countries across Asia, the Middle East, and Latin America. This complements its existing relationships with prominent global healthcare organizations such as Grupo Fleury in Brazil, Healius in Australia, Mayo Clinic Laboratories in the United States, and Unilabs in Europe. The company also maintains a research partnership with Mediford, underscoring its commitment to ongoing scientific advancement.
Addressing a Growing Global Need for Alzheimer’s Diagnostics
In announcing these partnerships, Dr. Joel Braunstein, CEO of C2N Diagnostics, emphasized the importance of expanding access to innovative diagnostics in regions where healthcare systems are under increasing strain.
“These new international partnerships are intended to broaden access to C2N’s innovative Precivity™ portfolio of blood tests in markets facing growing healthcare pressures given aging populations, a lack of dementia specialists, and inadequate PET infrastructure,” said Dr. Braunstein. “These partnerships are a testament to the science and research that have already assisted healthcare providers in delivering a clear picture of Alzheimer’s disease pathology to patients and their families in many countries. The growing burden of Alzheimer’s disease requires the healthcare system to explore new ways to offer less costly and more accessible diagnostic testing, and we look forward to helping more patients around the world receive an early and accurate diagnosis.”
Alzheimer’s disease currently affects more than 55 million people worldwide, according to the World Health Organization (WHO), with cases expected to nearly triple by 2050 as global populations age. The burden is particularly heavy in low- and middle-income countries, where diagnostic infrastructure is often insufficient to meet the needs of rapidly growing elderly populations. PET scans, one of the current gold-standard diagnostic tools for detecting amyloid plaques, are expensive, not widely available, and logistically challenging — often requiring patients to travel long distances to specialized facilities.
By introducing a blood-based test that can be performed in standard clinical settings, C2N is helping to remove these barriers and enable earlier, more accurate diagnoses that can guide patient care and support.
How the PrecivityAD2™ Blood Test Works
The PrecivityAD2™ test is intended for patients aged 55 years and older who present with signs or symptoms of cognitive impairment and are undergoing clinical evaluation for Alzheimer’s disease or other causes of cognitive decline. The process begins with a simple blood draw, after which the sample is sent to C2N’s specialized laboratory for analysis.
The test measures key biomarkers in the blood, including Aβ42/40 ratios and phosphorylated tau levels, which are closely associated with the underlying brain changes characteristic of Alzheimer’s disease. The results are then incorporated into an algorithm that provides healthcare providers with an objective measure of the likelihood that amyloid pathology is present.
The report generated from the test does not, on its own, provide a definitive Alzheimer’s diagnosis. Instead, it offers physicians an important piece of the diagnostic puzzle — one that can help determine whether further confirmatory testing or early intervention strategies are warranted.
Strong Clinical Validation and Published Accuracy Data
The PrecivityAD2™ blood test has undergone rigorous analytical and clinical validation. Notably, The Journal of the American Medical Association (JAMA) published findings from a large clinical care study evaluating the test’s ability to improve diagnostic accuracy in primary care settings — where the majority of patients with memory concerns first seek medical advice.
In this study, the PrecivityAD2™ algorithm demonstrated over 90% accuracy at a pre-defined binary cutoff when compared to established diagnostic methods such as CSF analysis and amyloid PET scans. The results were statistically significant, highlighting the test’s potential to serve as a reliable and accessible alternative in routine clinical practice.
This level of performance is particularly noteworthy because primary care physicians — who often see patients at the earliest stages of cognitive symptoms — typically lack access to advanced imaging or specialized neurological assessments. A blood test with this degree of accuracy can dramatically improve their ability to identify patients who are likely to benefit from referral to dementia specialists or from further confirmatory testing.
Commitment to Quality and Regulatory Standards
All of C2N’s Precivity™ tests are processed in the company’s CAP-accredited and CLIA-certified laboratory, ensuring compliance with the highest standards of laboratory quality and reliability. In addition, the tests are developed and performed under the ISO 13485:2016 quality management system standard, which governs medical device manufacturing and testing worldwide.
This rigorous adherence to quality protocols ensures that healthcare providers and patients can trust the consistency, reliability, and accuracy of every test result, regardless of geographic location.
The Global Impact of C2N’s Expansion
The addition of six new international partners is more than a business milestone — it represents a significant step toward democratizing access to advanced Alzheimer’s diagnostics. By strategically aligning with established laboratories and distributors in key global regions, C2N is ensuring that its technology reaches patients in areas that have historically faced barriers to cutting-edge medical innovation.
In Southeast Asia, for example, rapidly aging populations and limited availability of PET scanning facilities have created an urgent need for alternative diagnostic pathways. In Latin America, socioeconomic factors and healthcare infrastructure limitations have made it challenging for patients to obtain timely, accurate diagnoses. In parts of the Middle East, specialized dementia care is concentrated in urban centers, leaving rural populations underserved.
By integrating the PrecivityAD2™ test into the service offerings of trusted local laboratories, C2N and its partners are helping to close these gaps. This approach not only empowers physicians but also reduces the burden on patients and their families, who often face lengthy delays and high costs in their search for answers.
Innovation and Accessibility as Dual Priorities
While the expansion into seven additional countries marks a major step forward, C2N Diagnostics is not slowing down. The company continues to invest in research to enhance its portfolio of Precivity™ tests, exploring additional biomarkers and algorithm refinements that could further improve accuracy and broaden the range of detectable neurodegenerative conditions.
C2N is also exploring strategies to make its tests more widely available in public healthcare systems and to integrate them into routine dementia screening programs. This aligns with a broader movement in the medical community toward early detection and proactive intervention — an approach that could ultimately improve outcomes, reduce healthcare costs, and accelerate the development of new treatments.
C2N Diagnostics, LLC, is a specialty diagnostics company dedicated to advancing brain health diagnostics through its proprietary testing platforms. Guided by the principle of Clarity Through Innovation®, C2N is at the forefront of developing blood-based diagnostics for Alzheimer’s disease and other neurological conditions. Its flagship Precivity™ portfolio is designed to provide physicians with accessible, reliable tools for aiding in the early and accurate diagnosis of cognitive disorders.
